Study on Lixisenatide and Counterregulation to Hypoglycemia
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
In hypoglycemia, there is a counterregulation to restore glucose levels. An important part of
this counterregulation is the release of the hormone glucagon. Since the GLP-1 receptor
agonist lixisenatide has been shown to be associated with a low risk of hypoglycemia, this
study examines whether lixisenatide affects the glucagon response to hypoglycemia.